"Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
| Descriptor ID |
D011505
|
| MeSH Number(s) |
D08.811.913.696.620.682.725
|
| Concept/Terms |
Protein-Tyrosine Kinases- Protein-Tyrosine Kinases
- Kinases, Protein-Tyrosine
- Protein Tyrosine Kinases
- Tyrosine Kinase
- Kinase, Tyrosine
- Tyrosine Protein Kinase
- Kinase, Tyrosine Protein
- Tyrosylprotein Kinase
- Kinase, Tyrosylprotein
- Tyrosine-Specific Protein Kinase
- Kinase, Tyrosine-Specific Protein
- Protein Kinase, Tyrosine-Specific
- Tyrosine Specific Protein Kinase
- Tyrosine-Specific Protein Kinases
- Kinases, Tyrosine-Specific Protein
- Protein Kinases, Tyrosine-Specific
- Tyrosine Specific Protein Kinases
- Protein-Tyrosine Kinase
- Kinase, Protein-Tyrosine
- Protein Tyrosine Kinase
- Tyrosine Protein Kinases
- Kinases, Tyrosine Protein
- Protein Kinases, Tyrosine
|
Below are MeSH descriptors whose meaning is more general than "Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Protein-Tyrosine Kinases".
This graph shows the total number of publications written about "Protein-Tyrosine Kinases" by people in this website by year, and whether "Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 3 | 5 | 8 |
| 1998 | 3 | 2 | 5 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 3 | 5 |
| 2003 | 0 | 3 | 3 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 3 | 6 |
| 2006 | 0 | 3 | 3 |
| 2008 | 1 | 3 | 4 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 1 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein-Tyrosine Kinases" by people in Profiles.
-
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801.
-
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
-
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
-
Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis. Target Oncol. 2020 10; 15(5):589-598.
-
In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Philadelphia Chromosome-Positive?Acute Lymphoblastic Leukemia in First Complete Remission? Biol Blood Marrow Transplant. 2018 04; 24(4):637-638.
-
Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Cancer Med. 2016 08; 5(8):1883-9.
-
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. J Surg Oncol. 2016 Jan; 113(1):55-61.
-
Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells. J Autoimmun. 2015 Jul; 61:29-35.
-
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res. 2015 May 01; 21(9):2115-26.
-
Casein kinase 1d-dependent Wee1 protein degradation. J Biol Chem. 2014 Jul 04; 289(27):18893-903.